Annual SGA
$142.52 M
+$33.44 M+30.66%
December 31, 2023
Summary
- As of February 7, 2025, ESPR annual SGA is $142.52 million, with the most recent change of +$33.44 million (+30.66%) on December 31, 2023.
- During the last 3 years, ESPR annual SGA has fallen by -$57.09 million (-28.60%).
- ESPR annual SGA is now -28.60% below its all-time high of $199.62 million, reached on December 31, 2020.
Performance
ESPR SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$39.98 M
-$4.21 M-9.53%
September 30, 2024
Summary
- As of February 7, 2025, ESPR quarterly SGA is $39.98 million, with the most recent change of -$4.21 million (-9.53%) on September 30, 2024.
- Over the past year, ESPR quarterly SGA has dropped by -$4.21 million (-9.53%).
- ESPR quarterly SGA is now -35.06% below its all-time high of $61.55 million, reached on December 31, 2020.
Performance
ESPR Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$6.17 B
-$86.77 M-1.43%
September 30, 2024
Summary
- As of February 7, 2025, ESPR TTM SGA is -$6.17 billion, with the most recent change of -$86.77 million (-1.43%) on September 30, 2024.
- Over the past year, ESPR TTM SGA has dropped by -$6.33 billion (-3841.56%).
- ESPR TTM SGA is now -14593.14% below its all-time high of -$41.98 million.
Performance
ESPR TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
ESPR Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +30.7% | -9.5% | -3841.6% |
| 3 y3 years | -28.6% | -9.5% | -3841.6% |
| 5 y5 years | +330.6% | +116.5% | -9465.3% |
ESPR Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -22.9% | +30.7% | -12.0% | +65.6% | -52.4% | at low |
| 5 y | 5-year | -28.6% | +116.4% | -35.1% | +84.1% | -156.5% | at low |
| alltime | all time | -28.6% | +6360.7% | -35.1% | +7798.6% | <-9999.0% | at low |
Esperion Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $39.98 M(-9.5%) | $171.57 M(+4.1%) |
| Jun 2024 | - | $44.19 M(+5.2%) | $164.84 M(+6.6%) |
| Mar 2024 | - | $41.99 M(-7.6%) | $154.61 M(+8.5%) |
| Dec 2023 | $142.52 M(+30.7%) | $45.42 M(+36.7%) | $142.52 M(+17.6%) |
| Sep 2023 | - | $33.24 M(-2.1%) | $121.24 M(+7.3%) |
| Jun 2023 | - | $33.96 M(+13.6%) | $112.95 M(+4.0%) |
| Mar 2023 | - | $29.90 M(+23.9%) | $108.60 M(-0.4%) |
| Dec 2022 | $109.08 M(-41.0%) | $24.14 M(-3.3%) | $109.08 M(-11.5%) |
| Sep 2022 | - | $24.95 M(-15.7%) | $123.28 M(-10.4%) |
| Jun 2022 | - | $29.61 M(-2.5%) | $137.59 M(-10.8%) |
| Mar 2022 | - | $30.38 M(-20.8%) | $154.30 M(-16.6%) |
| Dec 2021 | $184.99 M(-7.3%) | $38.34 M(-2.4%) | $184.99 M(-11.2%) |
| Sep 2021 | - | $39.27 M(-15.2%) | $208.20 M(-4.4%) |
| Jun 2021 | - | $46.32 M(-24.1%) | $217.76 M(-0.6%) |
| Mar 2021 | - | $61.06 M(-0.8%) | $219.13 M(+9.8%) |
| Dec 2020 | $199.62 M(+203.1%) | $61.55 M(+26.1%) | $199.62 M(+24.9%) |
| Sep 2020 | - | $48.83 M(+2.4%) | $159.77 M(+23.5%) |
| Jun 2020 | - | $47.68 M(+14.7%) | $129.41 M(+35.9%) |
| Mar 2020 | - | $41.55 M(+91.4%) | $95.22 M(+44.6%) |
| Dec 2019 | $65.85 M(+99.0%) | $21.71 M(+17.6%) | $65.85 M(+19.0%) |
| Sep 2019 | - | $18.47 M(+36.9%) | $55.32 M(+20.6%) |
| Jun 2019 | - | $13.49 M(+10.8%) | $45.86 M(+16.6%) |
| Mar 2019 | - | $12.18 M(+9.0%) | $39.33 M(+18.8%) |
| Dec 2018 | $33.10 M(+54.8%) | $11.18 M(+24.0%) | $33.10 M(+21.8%) |
| Sep 2018 | - | $9.01 M(+29.5%) | $27.18 M(+14.0%) |
| Jun 2018 | - | $6.96 M(+16.8%) | $23.85 M(+6.9%) |
| Mar 2018 | - | $5.95 M(+13.3%) | $22.30 M(+4.3%) |
| Dec 2017 | $21.38 M | $5.26 M(-7.5%) | $21.38 M(+4.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | $5.68 M(+5.0%) | $20.53 M(+7.7%) |
| Jun 2017 | - | $5.41 M(+7.6%) | $19.06 M(+4.3%) |
| Mar 2017 | - | $5.03 M(+14.2%) | $18.28 M(-0.0%) |
| Dec 2016 | $18.28 M(-9.7%) | $4.40 M(+4.5%) | $18.28 M(-4.6%) |
| Sep 2016 | - | $4.21 M(-9.0%) | $19.16 M(-7.1%) |
| Jun 2016 | - | $4.63 M(-7.9%) | $20.61 M(-2.9%) |
| Mar 2016 | - | $5.03 M(-4.7%) | $21.23 M(+4.9%) |
| Dec 2015 | $20.24 M(+85.3%) | $5.28 M(-6.9%) | $20.24 M(+11.6%) |
| Sep 2015 | - | $5.67 M(+8.0%) | $18.14 M(+21.0%) |
| Jun 2015 | - | $5.25 M(+30.2%) | $14.99 M(+20.3%) |
| Mar 2015 | - | $4.04 M(+26.9%) | $12.47 M(+14.1%) |
| Dec 2014 | $10.92 M(+61.9%) | $3.18 M(+25.9%) | $10.92 M(+7.7%) |
| Sep 2014 | - | $2.53 M(-7.3%) | $10.14 M(+6.3%) |
| Jun 2014 | - | $2.73 M(+9.5%) | $9.54 M(+19.5%) |
| Mar 2014 | - | $2.49 M(+3.8%) | $7.98 M(+18.4%) |
| Dec 2013 | $6.75 M(+205.8%) | $2.40 M(+24.6%) | $6.75 M(+39.0%) |
| Sep 2013 | - | $1.92 M(+64.2%) | $4.85 M(+40.1%) |
| Jun 2013 | - | $1.17 M(-6.3%) | $3.46 M(+22.6%) |
| Mar 2013 | - | $1.25 M(+147.2%) | $2.82 M(+28.0%) |
| Dec 2012 | $2.21 M(-6.4%) | $506.10 K(-5.2%) | $2.21 M(+29.8%) |
| Sep 2012 | - | $533.80 K(+0.0%) | $1.70 M(+45.8%) |
| Jun 2012 | - | $533.70 K(-15.6%) | $1.17 M(+84.4%) |
| Mar 2012 | - | $632.40 K | $632.40 K |
| Dec 2011 | $2.36 M(-60.4%) | - | - |
| Dec 2002 | $5.96 M(+18.6%) | - | - |
| Dec 2001 | $5.02 M(+70.3%) | - | - |
| Dec 2000 | $2.95 M(+17.1%) | - | - |
| Dec 1999 | $2.52 M | - | - |
FAQ
- What is Esperion Therapeutics annual SGA?
- What is the all time high annual SGA for Esperion Therapeutics?
- What is Esperion Therapeutics annual SGA year-on-year change?
- What is Esperion Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Esperion Therapeutics?
- What is Esperion Therapeutics quarterly SGA year-on-year change?
- What is Esperion Therapeutics TTM SGA?
- What is the all time high TTM SGA for Esperion Therapeutics?
- What is Esperion Therapeutics TTM SGA year-on-year change?
What is Esperion Therapeutics annual SGA?
The current annual SGA of ESPR is $142.52 M
What is the all time high annual SGA for Esperion Therapeutics?
Esperion Therapeutics all-time high annual SGA is $199.62 M
What is Esperion Therapeutics annual SGA year-on-year change?
Over the past year, ESPR annual SGA has changed by +$33.44 M (+30.66%)
What is Esperion Therapeutics quarterly SGA?
The current quarterly SGA of ESPR is $39.98 M
What is the all time high quarterly SGA for Esperion Therapeutics?
Esperion Therapeutics all-time high quarterly SGA is $61.55 M
What is Esperion Therapeutics quarterly SGA year-on-year change?
Over the past year, ESPR quarterly SGA has changed by -$4.21 M (-9.53%)
What is Esperion Therapeutics TTM SGA?
The current TTM SGA of ESPR is -$6.17 B
What is the all time high TTM SGA for Esperion Therapeutics?
Esperion Therapeutics all-time high TTM SGA is -$41.98 M
What is Esperion Therapeutics TTM SGA year-on-year change?
Over the past year, ESPR TTM SGA has changed by -$6.33 B (-3841.56%)